Blue Earth Therapeutics snags $76M for both alpha and beta radiotherapies

The radiopharma field continues to buzz with private financings and more clinical-stage programs.

The latest is Oxford, UK-based Blue Earth Therapeutics, which unveiled a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Shionogi secures license for Maze’s Pompe disease treatment

Phase I clinical trial results indicated that MZE001 could become the first oral therapy option for Pompe disease. Credit: murat photographer / Shutterstock.com. Shionogi has

May 10, 2024

Immunic to Participate in Investor and Scientific Conferences in August – Biotech Investments

Issuer: Immunic, Inc. / Key word(s): Conference 01.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate

August 2, 2023

Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone

If you’re a drug company executive, you probably feel like you got up on the wrong side of bed. On Thursday night, President Biden proposed

March 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.